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Analogs ofsomatostatin (SRIF) such as octreotide exert antiproliferative effects
that are mediated directly by tumoral SRIF receptors or indirectly by down-
modulation of factors that stimulate tumor growth. Direct and indirect antipro-
liferative effects have been demonstrated in certain SRIF receptor-positive and
-negative human breast cancer models in nude mice, respectively. These
antiproliferative mechanisms are also being explored in other cancer types
including pancreatic cancer. While clinical pilot studies have indicated that a
fraction of pancreatic adenocarcinomas respond to high-dose octreotide treat-
ment, it is known from receptor autoradiographic and scintigraphic studies that
human pancreatic carcinomas fail to express SRIF receptors, in contrast to rat
pancreatic carcinomas or human endocrine pancreatic cancer. Studies on the
potential anticancer effect of octreotide on the growth of experimental human
pancreatic cancer and its SRIF receptor status have been controversial.
Therefore, we investigated in vivo the effects of octreotide on the growth of
MIA PaCa-2humanpancreatic carcinomas raised fromcultured cells with alow
passage number afterreceipt from theAmerican Type Culture Collection. Nude
mice bearing MIA PaCa-2 tumors were treated with a single injection of the
recently developed octreotide long-acting release formulation, "SMS pa LAR."
This treatment was well tolerated and resulted in a highly significant inhibition
oftumor growth during weeks three and eight after administration. MIA PaCa-
2 tumors were removed after eight weeks and processed for RT-PCR analysis
using probes specific for each of the five somatostatin receptor subtypes sstr-
sst5. This analysis revealed that MIA PaCa-2 tumors, like human pancreatic
adenocarcinomas, do not express any of the five SRIF receptor subtypes, sug-
gesting an indirect mode oftumor growth inhibition. In summary, the depot for-
mulation SMS pa LAR exerted long-lasting antiproliferative effects in SRIF
receptor-negative human pancreatic carcinomas in nude mice.
INTRODUCTION
The concept ofdirect and indirect cell growth inihibition by somatostatin (SRIF)b and
peptide analogs such as octreotide is used to explain their antiproliferative action in SRIF
receptor-positive and negative tumors [1, 2] (Figure 1). The direct effect implies that
octreotide binds to SRIF receptors on tumor cells leading to activation of a phosphotyro-
sine phosphatase (PTPase) and abrogation of cell growth that is induced via growth fac-
tor-regulated tyrosine kinases (TK) (Figure 1). Buscail et al. [3] demonstrated a positive
correlation between the activation of a phosphotyrosine phosphatase and antiproliferative
effects ofRC-160 oroctreotide in COS-7 andNIH 3T3 cells expressing sst2. A very recent
a To whom all correspondence should be addressed: Dr. Gisbert Weckbecker, c/o Novartis Pharma
Inc., Preclinical Research S-386.627, CH-4002 Basel, Switzerland. Tel.: 41-61-324-7936; Fax: 41-
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study by Srikant [4] in MCF-7 human breast adenocarcinoma cells revealed that treatment
with antiproliferative concentrations of octreotide leads to a translocation of phosphoty-
rosine phosphatase IC, a 66-kDa protein possessing two SH2 domains, from the cytosol
to the cell membrane in a G-protein-dependent manner. Membrane-associated phospho-
tyrosine phosphatase IC can promote association through the SH2 domains to phospho-
rylated EGF receptor, thereby terminating EGF receptor-induced mitogenic signalling.
Thus, there is good evidence for the concept ofdirect antiproliferative action at the mole-
cular level.
By contrast, support for the indirect mechanism is less clearcut, partially because it
can be studied only in vivo. The indirect mechanism is apparently operative through
downregulation of tumor growth stimuli including IGF-1, EGF or GH [5, 6] (Figure 1).
An indirect effect may occur in cancer cells both with and without SRIF receptors. Based
on the concept ofthe indirect effect SRIF analogs have been investigated as treatment for
SRIF receptor-negative cancers including pancreatic cancer. However, models for the
study ofthe indirect antitumor effects are rare. Controversial results were obtained in var-
ious laboratories with the MIA PaCa-2 human pancreatic carcinoma model. Gillespie et
al. [7] could neither detect SRIF receptors nor an effect ofRC-160 on the growth ofMIA
PaCa-2 cells in vitro. This suggested to us that MIA PaCa-2 tumors, provided that they
were sensitive to octreotide in the nude mouse, would be a candidate model to study the
indirect mechanism. By contrast, Radulovic et al. [8] demonstrated that this cell line was
growth inhibitedby RC-160 and also expressedbinding sites forradiolabeled RC-160 (Kd
4.3 nM, 75,000 sites/cell or 1.75 pmol/mg protein). Such differences in SRIF receptor
density could result from fluctuations in SRIF receptor (subtype) expression due to cell
handling, type ofmedia and sera used and differing cell passage number.
In this study, we used MIA PaCa-2 cells for generating tumor xenografts in nude
mice in order to explore the potential antiproliferative effect of a recently developed
depot formulation of octreotide, "SMS pa LAR." Tumor cell inoculation in the animals
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Figure 1. Concept ofthe direct and indirect effects exerted by SRIF analogs such as octreotide
on the proliferation of tumor cells with and without SRIF receptor (sst) expression. TK, pro-
tein tyrosine kinase; PTPase, phosphotyrosine phosphatase.
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was performed after a minimal number of passages following receipt of the cells from
the American Type Culture Collection in order to ensure a cellular phenotype very simi-
lar to the original one.
MATERIAL AND METHODS
The MIA PaCa-2 human pancreatic carcinoma cell line was obtained from the
American Type Culture Collection (ATCC, Rockville, MD). The cells used in this study
were from passage 8 to 10 after receipt from ATCC. SMS pa LAR is a depot formulation
of the pamoate salt of SMS 201-995 (octreotide), which was provided by our galenical
department (Dr. David Bodmer).
Tumor growth studies in vivo
We regularly check for the absence of mycoplasma in MIA PaCa-2 cells using bis-
benzimide staining and the GenProbe hybridization assay (San Diego, CA). Cultures are
propagated in DMEM supplemented with 10 percent fetal calf serum (FCS) at five per-
cent CO2. Cells are grown in the absence ofantibiotics or antifungal agents. Female nude
mice (nu/nu Balbc-A from Iffa Credo, Lyon, France) weighing 19-22 g, were kept in
groups of five animals in macrolon cages (type III, 16 x 22 x 11 cm). The cages were
placed in ventilated cabinets (Iffa Credo) that were maintained at 24 ± 1°C. The animals
had free access to drinking water and a pathogen-free rodent diet (Diet A, Kliba, Basel,
Switzerland). To initiate tumors from cultured cells, cells were trypsinized, and 107 tumor
cells (in 0.2 ml) were injected subcutaneously into both flanks of nude mice [9]. When
tumors had reached a volume of approximately 0.1 cm3, animals were randomized into
control and treatment groups. Control animals received a subcutaneous injection ofplace-
bo, while mice in the treatment group received a single injection of SMS pa LAR, 30
mg/kg subcutaneously. Animals were continuously observed for eight weeks with weekly
monitoring oftumor size and body weight. The size ofthe tumors was determined with a
caliper. To calculate the tumor volume the equation "volume (ellipsoid) = length x depth
x height x 0.52" was used. For statistical calculations, Student's t-test was applied.
RT-PCR analysis ofsst status ofMIA PaCa-2 cells and tumors
Eight weeks after injection of SMS pa LAR, tumors were removed under anesthesia
(Forene® fromAbbott, Cham, Switzerland) and frozen in liquid nitrogen until isolation of
poly(A)+-RNA for receptor subtype-specific RT-PCR analysis of sst1-sst5. This was per-
formed essentially as described previously [10] except forthe primerpairs for the sst1 and
sst4 receptor specific RT-PCRs. For sst1, we used the primers RS180 (5'-TCA GCT GGG
ATG TTC CCC AAT G-3') and RS190 (5'-GTC GTC TTG CTC GGC GAA CAC G-3'),
and for sst4 the primers HS48 (5'-ACC AAC ATC TAC CTG CTC AAC CTG G-3') and
HS49 (5'-GCA TAG TAG TCC AGG GGC TC-3') were used.
RESULTS AND DISCUSSION
Nude mice bearing MIA PaCa-2 tumors were treated either with placebo or a single
injection of the recently developed octreotide long-acting release formulation SMS pa
LAR (Figure 2). The treatment with SMS pa LAR resulted in a highly significant (p <
.0002) inhibition of tumor growth for the observation period of weeks three to eight. The
mean volume oftreated tumors was 25.8 percent of control at the end of the experiment.
Since thebody weight ofoctreotide-treated mice did not show the distinct drop that is usu-
ally observed with most cytotoxic anticancers, the depot formulation is apparently well
tolerated (Table 1).
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Figure 2 Effect of a single injection ofSMS pa LAR, a depot formulation ofoctreotide, on the
growth of MIA PaCa-2 human pancreatic carcinomas in nude mice.
The SRIF receptor status of 12 individual MIA PaCa-2 tumors was determined at the
end ofthe eight-week experiment. Tumors were excised and processed for RT-PCR analy-
sis using probes specific for each of the five somatostatin receptor subtypes sstl-sst5
(Figure 3). This analysis revealed that these MIA PaCa-2 tumors, under the experimental
conditions described, failed to express detectable levels of any of the five somatostatin
receptor subtypes except for two tumors that gave very weak RT-PCR signals for the sst3
mRNA. It should be noted that for sst2, the only human SRIF receptor with high affinity
for octreotide, all tumors analyzed were negative in the sensitive human (and in addition
mouse) specific RT-PCR assay. Reaction conditions were controlled by including negative
and positive (human sst2 cDNA) controls (Figure 3). Interestingly, there was no difference
in the findings when the control tumors were compared with the SMS pa LAR-treated
tumors (Figure 3). The same negative results were obtained by analyzing MIA PaCa-2
cells in vitro (data not shown). Thus, the MIA PaCa-2 model is apparently identical in this
aspect to human pancreatic adenocarcinomas which are SRIF receptor-negative too.
Table 1. Body weight change (g) ofnude mice bearing MIA PaCa-2 tumors following injection
ofplacebo or SMS pa LAR (same mice as in Figure 2).
Day Control +SE SMS pa LAR +SE
0 21.9 0.6 21.1 0.5
7 22.2 0.4 21.2 0.4
28 22.3 0.5 21.4 0.9
56 23.3 1.0 22.1 0.9Weckbecker et al.: Octreotide as inhibitor ofpancreatic carcinoma growth
_ S _~~414 bp
...............~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.a..
i 2 3 7 x U 12 I 1 4 17 i I7 S X I) \
Figure 3 RT-PCR analysis ofindividual MIA PaCa-2 tumors. Gel analysis ofRT-PCR products
after a 40-cycle RT-PCR specific for sst2. The gel shows no detectable product in the 12 individual
tumor RNA preparations (lanes 1-12) and in the negative controls (lane 13 hsst lane 15 hsst lane
16 hsst4, lane 17 hsst, cDNA, lane 19 water control). Positive controls (lane 14 human sst2 cIDNA,
lane 18 human genomic DNA {sst2 is intronless}) show the expected product of414 bp. Tumors #1-
5 were from SMS pa LAR-treated mice and single tumors #6-12 were from control animals. The
amount and integrity of mRNA was verified by (,B-actin RT-PCR (not shown) [10].
The precise nature ofthe indirect mechanism ofoctreotide in the MIA PaCa-2 model
needs to be further addressed. Our recent studies in various species clearly indicate that
octreotide leads to dose-dependent decrease of IGF-1 levels. This may be interesting in
the context that pancreatic cancer growth is subject to control by the IGF-1 system. The
indirect effects ofoctreotide on tumor growth may also include its antiangiogenic proper-
ties [ 1]. Reubi et al. [12] showed that veins surrounding human cancer express high lev-
els of somatostatin receptors. Since Tyr3-octreotide was bound with high affinity, the
tumor-associated veins probably express sst2 and/or sst5. Danesi et al. [13] demonstrated
the antiangiogenic properties ofoctreotide in various angiogenesis models in vivo such as
the rat cornea model and the rat mesentery model.
An important factor for achieving antiproliferative effects is to maintain high
octreotide plasma levels for extended time periods. In a separate experiment performed
under identical conditions in the AR42J pancreatic tumor nude mouse model, the mean
plasma concentration (±SE) of octreotide three weeks after a single injection of SMS pa
LAR was 9.3 ± 1.6 nM. This treatment was associated with a potent inhibition ofAR42J
tumor growth (data not shown). Plasma levels in this range were also shown previoulsy to
exert long-lasting antiproliferative effects in the ZR-75-1 mammary tumor bearing nude
mouse [9].
Upp et al. [14] demonstrated that the growth ofSKI human pancreatic adenocarcino-
mas in nude mice is inhibited by octreotide treatment. However, the SRIF receptor status
of SKI tumors used in this investigation has not been reported. A very recent study by
Fisher et al. [15] also showed that MIA PaCa-2 tumors in nude mice were inhibited by
continuous administration of octreotide, while the other pancreatic tumor models tested
were unresponsive. In contrast to our study, these MIA PaCa-2 tumors did express SRIF
receptors (sst2). Moreover, in a pilot clinical trial, high-dose therapy with octreotide was
associated with a tumor response in a fraction of the treated patients [16]. The still limit-
ed amount ofpreclinical and clinical data suggest that certain pancreatic adenocarcinomas
respond to SRIF analog treatment. Due to the absence of detectable SRIF receptors in
human pancreatic cancer, the underlying antiproliferative effect is expected to be indirect.
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In summary, a single injection ofthe depot formulation ofSMS pa LAR was well tol-
erated and exerted long-lasting antiproliferative effects in SRIF receptor-negative human
pancreatic carcinomas in nude mice.
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